Day: December 16, 2024

VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Miata Metals Corp. (CSE: MMET) (FSE: 8NQ) (“Miata” or the “Company”) is pleased to provide an operational update on the Company’s upcoming drill program at the Sela Creek Gold Project (“Sela Creek”) as well as a comprehensive summary of significant achievements in 2024, resulting in a gold project portfolio that covers over 400 km2 of the Guiana Shield in Suriname. Operational Update on Sela Creek Gold Project To improve access and circumvent exceedingly low water levels in the Tapanahony River, which serves as an important access route to the Sela Creek project, Miata is completing upgrades on a road that will allow for transport of the drill rig and other heavy equipment directly to site. The outcome of this work, once completed, should result...

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders Date        16 December 2024 Share buyback programme – week 50 The share buyback programme runs in the period 1 February 2024 up to and including 27 January 2025, see company announcement of 31 January 2024. Part I of the programme, for DKK 750 million, was completed on 27 June 2024, see company announcement of 28 June 2024. Part II of the programme, for DKK 775 million and a maximum of 1,550,000 shares, is for execution in the period 28 June 2024 – 27 January 2025. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” rules. The following transactions have...

UAB “Valstybės investicinis kapitalas” (hereinafter – the Company) announces that, by decision of the Company’s Board of Directors, Mr. Vaidas Daktariūnas has been appointed as Acting CEO effective December 7, 2024. He replaces Mr. Robertas Vyšniauskas, who has stepped down from the CEO position as of that date. This change aligns with the Company’s strategic objectives and will ensure a smooth transition period. The Company extends its gratitude to Mr. Robertas Vyšniauskas for his contributions during his tenure. The Company is committed to complying with all applicable legal regulations and Nasdaq rules, including the public disclosure of information. Any additional details regarding this decision will be disclosed promptly if required under applicable regulations. The Board of UAB “Valstybės investicinis...

Committed to Full Continuity in Delivering Next-Generation BAW High-Band RF Filters to Customers Around the World Filing to Ensure Business Sold Free and Clear of Qorvo Infringement Following Final Judgement and Required Cleansing Process Charlotte, NC, Dec. 16, 2024 (GLOBE NEWSWIRE) — Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Committed to Full Continuity in Delivering Next-Generation BAW High-Band RF Filters to Customers Around the World Filing to Ensure Business Sold Free and Clear of Qorvo Infringement Following Final Judgement and Required Cleansing Process Charlotte, NC – DECEMBER 16, 2024 – Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea’s hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US). Innoviva Specialty Therapeutics is a US-based biopharmaceutical company with an established hospital sales force and a core competence in commercializing anti-infective medicines. David Veitch, Chief Executive Officer of Basilea, stated: “We are very pleased with our...

NEW YORK, Dec. 15, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN), (“Roadzen” or the “Company”), a global leader in AI at the convergence of insurance and mobility, today announced the pricing of an underwritten public offering of 2,000,000 ordinary shares (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) at a public offering price of $1.25 per share (inclusive of the Pre-Funded Warrant exercise price), for gross proceeds of $2,500,000, before deducting underwriting discounts, commissions and offering expenses. All of the ordinary shares (and/or Pre-funded Warrants) are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares (and/or Pre-funded Warrants) at the public offering price less discounts and...